Publications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

20-11-2019

Nature reviews. Immunology

Defining 'T cell exhaustion'.

01-11-2019

Cell reports

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.

01-10-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

01-10-2019

European urology

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

01-10-2019

The Lancet. Oncology

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

01-09-2019

ESMO open

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

20-08-2019

Cell

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

25-07-2019

Cancers

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

18-07-2019

The Lancet. Oncology

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

01-07-2019

The Lancet. Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

01-07-2019

Future oncology (London, England)

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

01-07-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

01-07-2019

Immuno-oncology technology

A user's perspective on GeoMx^TM digital spatial profiling.

01-07-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

01-07-2019

European journal of cancer (Oxford, England : 1990)

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

01-07-2019

Journal of oncology

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

12-06-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

01-06-2019

Nature medicine

Combining checkpoint inhibition and targeted therapy in melanoma.

01-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Journal of immunotherapy (Hagerstown, Md. : 1997)

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.

31-05-2019

Cancer immunology, immunotherapy : CII

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

01-05-2019

The British journal of surgery

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

01-04-2019

Oncotarget

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

05-03-2019

European urology

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

01-03-2019

Oncoimmunology

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

07-02-2019

Cell

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

07-02-2019

Oncoimmunology

Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

05-02-2019

Cancer letters

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

01-02-2019

JAMA oncology

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

01-02-2019

European journal of cancer (Oxford, England : 1990)

An open-label, multicentre safety study of vemurafenib in patients with BRAF^V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

01-01-2019

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

JAAD case reports

Remission of psoriasis during treatment with sorafenib.

01-11-2018

Cancer immunology, immunotherapy : CII

Targeting tumor-associated acidity in cancer immunotherapy.

01-09-2018

European journal of cancer (Oxford, England : 1990)

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

01-09-2018

Annals of oncology : official journal of the European Society for Medical Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

01-08-2018

American journal of clinical dermatology

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

01-06-2018

The New England journal of medicine

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

10-05-2018

Melanoma research

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

01-04-2018

ESMO open

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

02-02-2018

Nature medicine

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

01-02-2018

European journal of cancer (Oxford, England : 1990)

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

01-11-2017

Urology

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

01-11-2017

JCO precision oncology

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

01-11-2017

Lancet (London, England)

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

21-10-2017

Nature

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

12-10-2017

Nature

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

07-09-2017

European journal of cancer (Oxford, England : 1990)

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF^V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

01-07-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

01-04-2017

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

Defining 'T cell exhaustion'.

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

A user's perspective on GeoMxTM digital spatial profiling.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

Combining checkpoint inhibition and targeted therapy in melanoma.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Remission of psoriasis during treatment with sorafenib.

Targeting tumor-associated acidity in cancer immunotherapy.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

This site uses cookies

A user's perspective on GeoMx^TM digital spatial profiling.

Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

An open-label, multicentre safety study of vemurafenib in patients with BRAF^V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF^V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.